This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease | MicrobiomeTrials
← Back to trials NCT07683325
NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-10-30Est. Completion: 2028-12-31
Enrollment target: 320 participantsLocations Synergy Healthcare, LLC, Bradenton, Florida, United States Albany Gastroenterology Consultants, Albany, New York, United States University Gastroenterology, Providence, Rhode Island, United States GI Alliance - Fort Worth, Fort Worth, Texas, United States Amel Med LLC, Georgetown, Texas, United States Other microbiome trials you might be interested in Crohn Disease Fibrostenotic Crohn's Disease CD - Crohn's Disease
The goal of this retrospective observational study is to learn whether artificial intelligence-based digital pathology c…
Seville, Spain Est. completion Mar 15, 2027
Fibrostenotic Crohn's Disease
This is an open, two-part study in healthy male volunteers, aged 30-65 years.
This trial aims to understand how the hum…
Nottingham, United Kingdom Est. completion Sep 26, 2026